Symposium:
120. Viral Hepatitis
Friday, October 6, 2017: 8:30 AM-10:00 AM
Room: 06AB

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • evaluate new treatment options for HCV and for HBV
  • assess appropriate follow up and monitoring for patients treated for HCV
  • describe how to manage patients who fail on first line HCV treatment options

Target Audience: Clinicians, Fellows, HIV clinicians, HIV specialists, Infectious diseases pediatricians, Infectious diseases physicians, Members-in-training, Nurses, Pharmacists, Public health practitioners

Tracks: HIV-STD-TB, Adult ID


Moderators:  Eric Daar, MD, Harbor-UCLA Medical Center and David L. Wyles, MD, Denver Health Medical Center

Presentations:
8:30 AM
941
HCV and HBV Treatment Updates 2017
Susanna Naggie, MD, MHS

9:45 AM
Q&A

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-272-L01-P

Disclosures:

E. Daar, Bristol Myers Squibb: Consultant , Consulting fee
Gilead: Consultant and Grant Investigator , Consulting fee and Research grant
Janssen: Consultant , Consulting fee
Merck: Consultant and Grant Investigator , Consulting fee and Research grant
Teva: Consultant , Consulting fee
Theratechnologies: Consultant , Consulting fee
ViiV: Consultant and Grant Investigator , Consulting fee and Grant recipient

D. L. Wyles, AbbVie: Consultant , Research Contractor and Scientific Advisor , Consulting fee and Research support
Gilead: Consultant , Grant Investigator and Research Contractor , Consulting fee , Research grant and Research support
Merck: Consultant and Research Contractor , Consulting fee and Research support

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.